Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 4
1951 2
1952 1
1954 1
1957 1
1960 3
1961 1
1962 1
1963 2
1964 3
1965 1
1966 3
1967 3
1968 4
1970 1
1971 1
1973 5
1974 1
1975 5
1976 18
1977 199
1978 558
1979 720
1980 826
1981 897
1982 1030
1983 1028
1984 1231
1985 1358
1986 1305
1987 1307
1988 1387
1989 1956
1990 1961
1991 2092
1992 2220
1993 2226
1994 2577
1995 2497
1996 2783
1997 3081
1998 3053
1999 3177
2000 3744
2001 3637
2002 4074
2003 4734
2004 4840
2005 5538
2006 5679
2007 6358
2008 7027
2009 7688
2010 8550
2011 9098
2012 9519
2013 10360
2014 11144
2015 11563
2016 11026
2017 10159
2018 9186
2019 9643
2020 8645
2021 7355
2022 4458
2023 3908
2024 5784
2025 6274
2026 3384

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208,121 results

Results by year

Filters applied: . Clear all
Page 1
Management of Differentiated Thyroid Cancer.
Hegedüs L, Wirth LJ, Tuttle RM. Hegedüs L, et al. N Engl J Med. 2026 Jun 18;394(23):2340-2355. doi: 10.1056/NEJMra2416814. N Engl J Med. 2026. PMID: 42308485 Review.
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Yue D, Huang M, Song P, Chen Y, Li B, Fu J, Guo J, Cheng C, Chen Q, Xu S, Liu H, Lv F, Hu J, Jiang K, Mao W, Shen B, Ye F, Li J, Zhang X, Guo S, Yu B, Zhu Y, Wu M, Zheng W, Chen F, He Z, Bai Y, Xin H, Chen K, Mao N, Zhang Y, Wang B, Zhang L, Chen X, Mei X, Miao L, Wang R, Li G, Yao J, Zhao J, Chen C, Liu J, Wei L, Yan X, Jin B, Liu X, Liu Z, Tian H, Xing W, Yang L, Ge D, Li X, Li S, Song Y, Zang A, Zhang D, Zhuang W, Liu Z, Yuan X, Fu T, Shen Z, Zhang X, Cao Q, Zhao L, Mao L, Ding L, Lu Y, Wang C; ELEVATE Study Group. Yue D, et al. N Engl J Med. 2026 Jul 9;395(2):151-161. doi: 10.1056/NEJMoa2518990. N Engl J Med. 2026. PMID: 42418775 Clinical Trial.
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.
Kato T, Dong X, Takahashi T, Soparattanapaisarn N, Geater SL, Wang CL, Arriola E, Moiseenko F, Thompson L, Grainger E, Armenteros-Monterroso E, Evans A, Bolanos A, Ramalingam SS, Lu S. Kato T, et al. Lung Cancer. 2026 Aug;218:109486. doi: 10.1016/j.lungcan.2026.109486. Epub 2026 Jun 6. Lung Cancer. 2026. PMID: 42296617 Free article. Clinical Trial.
Surgical Considerations for Primary Liver Neoplasms.
Cheung DC, Stucky CC. Cheung DC, et al. Hematol Oncol Clin North Am. 2026 Aug;40(4):507-519. doi: 10.1016/j.hoc.2026.05.009. Epub 2026 Jun 17. Hematol Oncol Clin North Am. 2026. PMID: 42309948 Review.
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.
Folprecht G, Stasik S, Reinacher-Schick A, Weiss L, Goekkurt E, Jacobasch L, Conradi L, Kröcher A, Hofheinz RD, Liersch R, Martens UM, Chater J, Fuchs M, Riera Knorrenschild JU, Schubert J, Klimova A, Reinhardt L, Sperling C, von Tresckow J, Weitz J, Aust DE, Tannapfel A, Christmann J, Thiede C. Folprecht G, et al. Ann Oncol. 2026 Aug;37(8):1120-1132. doi: 10.1016/j.annonc.2026.05.001. Epub 2026 May 31. Ann Oncol. 2026. PMID: 42225236 Free article. Clinical Trial.
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Leitch AM, Lyons J, McCloskey S, McShane M, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Speers C, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2026 Jul;24(7):e260033. doi: 10.6004/jnccn.2026.0033. J Natl Compr Canc Netw. 2026. PMID: 42425164
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
Seefat RL, Vliek SB, de Jong VMT, Balduzzi S, Mandjes IA, Retèl VP, Eekhout I, Delfos M, Schot M, Holtkamp MJ, van Rosmalen MM, Leeneman B, Blommestein H, Huitema ADR, Rosenberg EH, Nederlof PM, Chan TWS, van Rhenen A, Wondergem MJ, Schaap NPM, Snijders TJF, Van der Poel MWM, Plattel WJ, van Werkhoven E, van Tinteren H, Smidt ML, Wesseling J, Jonkers J, Rottenberg S, Vrancken Peeters MTFD, Voermans C, Maduro JH, Kroep JR, Schroder CP, Kuip EJM, Gonçalves A, Nuver J, Wymenga ANM, Bijlsma RM, van der Wall E, Konings IRHM, Tjan-Heijnen VCG, Jongen-Lavrencic M, Jager A, Linn SC. Seefat RL, et al. Lancet Oncol. 2026 Jul;27(7):795-807. doi: 10.1016/S1470-2045(26)00131-2. Lancet Oncol. 2026. PMID: 42372741 Clinical Trial.
208,121 results
You have reached the last available page of results. Please see the User Guide for more information.